Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively
Eli Lilly Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively remained flat by 0.0% to $590.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 0.4%, from $592.60M to $590.00M. Over 5 years (FY 2020 to FY 2025), Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively shows relatively stable performance with a -0.3% CAGR.
Analysis
How to read this metric
Changes are typically driven by stock issuances or share cancellations rather than operational performance.
Detailed definition
This represents the par value of the common shares issued and outstanding. It is a fundamental component of shareholders...
Peer comparison
Standard accounting line item; usually remains stable unless there is a significant equity financing event.
equity_common_stock_valueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $598.10M | $598.20M | $596.30M | $594.10M | $594.10M | $594.10M | $594.10M | $593.50M | $593.60M | $593.60M | $593.60M | $594.20M | $594.20M | $593.90M | $592.00M | $592.60M | $592.00M | $591.40M | $590.00M | $590.00M |
| QoQ Change | — | +0.0% | -0.3% | -0.4% | +0.0% | +0.0% | +0.0% | -0.1% | +0.0% | +0.0% | +0.0% | +0.1% | +0.0% | -0.1% | -0.3% | +0.1% | -0.1% | -0.1% | -0.2% | +0.0% |
| YoY Change | — | — | — | — | -0.7% | -0.7% | -0.4% | -0.1% | -0.1% | -0.1% | -0.1% | +0.1% | +0.1% | +0.1% | -0.3% | -0.3% | -0.4% | -0.4% | -0.3% | -0.4% |
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively at Other Companies
Frequently Asked Questions
- What is Eli Lilly's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively?
- Eli Lilly (LLY) reported common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively of $590.00M in Q1 2026.
- How has Eli Lilly's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively changed year-over-year?
- Eli Lilly's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively decreased by 0.4% year-over-year, from $592.60M to $590.00M.
- What is the long-term trend for Eli Lilly's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively?
- Over 5 years (2020 to 2025), Eli Lilly's common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively has grown at a -0.3% compound annual growth rate (CAGR), from $598.20M to $590.00M.
- What does common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively mean?
- The nominal par value of all common shares issued by the company.